文献速递药物不良反应与药物警戒

尼达尼布在纤维化间质性肺疾病中的应用综述

Nintedanib: A Review in Fibrotic Interstitial Lung Diseases.
PubMed 文献 · Drugs · 2021-03-25

尼达尼布是一种具有抗纤维化作用的细胞内酪氨酸激酶抑制剂,已在多国III期试验中显著降低IPF、其他进展性纤维化ILD和SSc-ILD成人患者的FVC年下降率。真实世界经验支持其延缓IPF进展的有效性,最常见不良事件为腹泻和恶心,多数可管理。尼达尼布是首个获批用于其他慢性纤维化进展表型ILD和SSc-ILD的药物。

要点

  • 尼达尼布显著降低IPF、进展性纤维化ILD和SSc-ILD患者的FVC年下降率。
  • IPF患者中尼达尼布临床获益可持续超过4年治疗。
  • 最常见不良事件为腹泻和恶心,多数患者可管理。

核心结论

  • 尼达尼布是IPF的重要治疗选择,也是首个获批用于其他慢性纤维化进展表型ILD和SSc-ILD的药物。

研究设计与样本

  • 综述汇总了多国III期试验和真实世界研究,评估尼达尼布在IPF、其他进展性纤维化ILD和SSc-ILD中的疗效与安全性。

主要发现

  • 尼达尼布显著降低IPF、其他进展性纤维化ILD和SSc-ILD成人患者的FVC年下降率。
  • IPF合并严重气体交换损害患者的FVC下降改善与较轻疾病患者相当。
  • 真实世界经验支持尼达尼布延缓IPF进展的有效性。
  • 最常见不良事件为腹泻和恶心,多数患者可管理。
  • 全球药物警戒数据未出现新的安全信号。

临床怎么用

  • 尼达尼布可用于IPF、其他慢性纤维化进展表型ILD和SSc-ILD成人患者以延缓肺功能下降。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Progressive fibrosing interstitial lung diseases (ILDs) involve similar pathophysiological processes, indicating the potential for common approaches to treatment. Nintedanib (Ofev®), an intracellular tyrosine kinase inhibitor (TKI) with antifibrotic properties, was one of the first drugs approved for use in idiopathic pulmonary fibrosis (IPF) and has more recently been approved for use in other chronic fibrosing ILDs with a progressive phenotype and systemic sclerosis-associated ILD (SSc-ILD). In multinational phase III trials, nintedanib significantly reduced the annual rate of decline in forced vital capacity (FVC) in adults with IPF, other progressive fibrosing ILDs and SSc-ILD. Reductions in FVC decline with nintedanib in patients with IPF and severe gas exchange impairment were comparable to those in patients with milder disease. Real-world experience in patients with IPF supports the effectiveness of nintedanib in slowing ILD progression. Nintedanib had a manageable tolerability profile in patients with fibrotic ILDs in clinical trials and real-world studies. No new safety signals have emerged from global pharmacovigilance data. Nintedanib continues to represent an important therapeutic option in patients with IPF and is the first drug to be approved for use in patients with other chronic fibrosing ILDs with a progressive phenotype or SSc-ILD, with these approvals expanding the range of fibrotic ILDs for which nintedanib can be prescribed. Treatment options for fibrotic interstitial lung diseases (ILDs) that involve progressive lung function decline have historically been limited. Nintedanib (Ofev®) was one of the first antifibrotic drugs to be approved for use in idiopathic pulmonary fibrosis and is now also approved for use in other chronic fibrosing ILDs with a progressive phenotype and systemic sclerosis-associated ILD (SSc-ILD). Nintedanib reduced lung function deterioration in patients with idiopathic pulmonary fibrosis, other chronic fibrosing ILDs with a progressive phenotype and SSc-ILD in well-designed clinical trials. In patients with idiopathic pulmonary fibrosis, the clinical benefit of nintedanib was shown to persist over more than 4 years of treatment. The most common adverse events in nintedanib recipients were diarrhoea and nausea, which were manageable in the majority of patients. Real-world experience supports the effectiveness and acceptable safety of nintedanib. Nintedanib remains an important treatment option for patients with idiopathic pulmonary fibrosis and is the first drug to be approved for use in patients with other chronic fibrosing ILDs with a progressive phenotype and SSc-ILD.

来源:Drugs,查看原文。版权归原作者所有。

引用

  1. Lamb YN. Nintedanib: A Review in Fibrotic Interstitial Lung Diseases. Drugs. 2021. PMID: 33765296. doi:10.1007/s40265-021-01487-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。